[{"address1": "One Cavendish Place", "address2": "4th Floor", "city": "London", "zip": "W1G 0QF", "country": "United Kingdom", "phone": "44 33 3023 7300", "website": "https://www.mereobiopharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 33, "companyOfficers": [{"maxAge": 1, "name": "Dr. Denise Vera Scots-Knight Ph.D.", "age": 64, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 890562, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles Edward Sermon", "age": 54, "title": "Co-Founder, General Counsel, Business Development & Company Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 625786, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Fox CPA", "age": 42, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 569768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John P. Richard M.B.A.", "age": 66, "title": "Co-Founder & Chief Business Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John A. Lewicki Ph.D.", "age": 71, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jackie  Parkin", "age": 65, "title": "Senior VP & Therapeutic Head", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Hughes-Wilson", "age": 52, "title": "Chief of Patient Access & Commercial Planning", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suba  Krishnan", "age": 58, "title": "Senior Vice President of Clinical Development", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bo  Kara", "title": "Senior VP and Head of Pharmaceutical Development & CMC", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.21, "open": 4.18, "dayLow": 4.132, "dayHigh": 4.31, "regularMarketPreviousClose": 4.21, "regularMarketOpen": 4.18, "regularMarketDayLow": 4.132, "regularMarketDayHigh": 4.31, "beta": 0.965, "forwardPE": -141.66667, "volume": 482565, "regularMarketVolume": 482565, "averageVolume": 803976, "averageVolume10days": 538400, "averageDailyVolume10Day": 538400, "bid": 4.24, "ask": 4.27, "bidSize": 200, "askSize": 200, "marketCap": 653875200, "fiftyTwoWeekLow": 1.86, "fiftyTwoWeekHigh": 5.02, "priceToSalesTrailing12Months": 653.8752, "fiftyDayAverage": 4.3712, "twoHundredDayAverage": 3.720725, "currency": "USD", "enterpriseValue": 3182838784, "floatShares": 485069441, "sharesOutstanding": 153852992, "sharesShort": 5158385, "sharesShortPriorMonth": 4541368, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0335, "heldPercentInsiders": 0.010249999, "heldPercentInstitutions": 0.65459, "shortRatio": 6.58, "shortPercentOfFloat": 0.0398, "bookValue": 0.512, "priceToBook": 8.300781, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -36847000, "trailingEps": -0.25, "forwardEps": -0.03, "enterpriseToRevenue": 3182.839, "enterpriseToEbitda": -85.306, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MREO", "underlyingSymbol": "MREO", "shortName": "Mereo BioPharma Group plc", "longName": "Mereo BioPharma Group plc", "firstTradeDateEpochUtc": 1556112600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2bb59234-2dd4-3418-a5f3-ada28f11788c", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.25, "targetHighPrice": 8.06, "targetLowPrice": 6.04, "targetMeanPrice": 7.25, "targetMedianPrice": 7.05, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 87431000, "totalCashPerShare": 0.114, "ebitda": -37311000, "totalDebt": 6162000, "quickRatio": 5.784, "currentRatio": 6.074, "totalRevenue": 1000000, "debtToEquity": 7.835, "revenuePerShare": 0.007, "returnOnAssets": -0.23857, "returnOnEquity": -0.48473, "freeCashflow": -15369286, "operatingCashflow": -20025000, "grossMargins": 1.509, "operatingMargins": -37.904, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]